A Multi-center, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Compare Cessation Versus Continuation of Long-term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma (201810)

Trial Profile

A Multi-center, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Compare Cessation Versus Continuation of Long-term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma (201810)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2018

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 12 Jan 2018 This trial has been completed in Germany (End date: 2017-11-22)
    • 14 Aug 2017 Planned End Date changed from 30 Jan 2019 to 25 Apr 2019.
    • 14 Aug 2017 Planned primary completion date changed from 30 Jan 2019 to 25 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top